Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Core Insights - Corcept Therapeutics Incorporated presented new late-breaking data from its pivotal Phase 3 ROSELLA trial, focusing on the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [1] Company Overview - Corcept Therapeutics is a commercial-stage company that specializes in discovering and developing medications aimed at treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol hormone effects [1]